Year: 2024

Amsterdam and Dubai, 21 October 2024: VEON Ltd. (Nasdaq: VEON; Euronext Amsterdam: VEON), a global digital operator (“VEON” or the “Company”), today announces that it has commenced the process for the delisting of its common shares from trading on Euronext Amsterdam (the “Euronext Amsterdam Delisting”), following the approval of Euronext Amsterdam. The Company’s last day of trading on Euronext Amsterdam will be 22 November 2024 (the “Last Trading Date”) and the delisting will be effective from 25 November 2024. With this move, VEON will consolidate the trading of its shares on the Nasdaq Capital Market (“Nasdaq”), which will be the platform for the trading of VEON’s American depositary shares, each representing 25 Common Shares (the “ADSs”). Following the Last Trading Date, all public trading of equity securities in the Company will take...

Fossar fjárfestingarbanki hf. hefur lokið sölu á nýjum skuldabréfaflokki FOS 281026 sem gefinn er út undir 12.000.000.000 útgáfuramma bankans. FOS 281026 er almennur skuldabréfaflokkur sem ber 9,2% vexti, sem greiddir eru tvisvar á ári til lokagjalddaga 28. október 2026. Seld voru skuldabréf að nafnverði 1.500 m.kr. á ávöxtunarkröfunni 9,48%. Skuldabréfin voru seld í einkaútgáfu (e. private placement). Nafnverðseining skuldabréfanna er 20 m.kr. og var útboðið því undanþegið gerð lýsingar á grundvelli c og d-liðar 4. mgr. 1. gr. reglugerðar Evrópusambandsins og ráðsins (ESB) nr. 2017/1129. Stefnt er að töku skuldabréfanna til viðskipta á markaði Nasdaq Iceland. Markaðsviðskipti Fossa fjárfestingarbanka hf. hafa umsjón með útgáfu og sölu skuldabréfanna sem og töku þeirra til viðskipta á markaði Nasdaq Iceland. Grunnlýsing, endanlegir skilmálar...

ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) —Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum DIAMOND program committees expanded with globally renowned retina expertsIf approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DMEOculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina experts. Substantial enrollment progress was achieved since the end of Q2 2024 through early October, with ~70% of patients enrolled in the Phase...

Volta Finance Limited (VTA / VTAS)September 2024 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, October 21st, 2024 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for September 2024. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear investors, Volta Finance recorded a net performance of +2.3% in September bringing the year-to-date return to +13.5%. This positive performance is built on the strong performance of its CLO equity investments through the month, Volta being almost fully invested in CLO Equity and debt tranches. Markets found some momentum in September on the back of a rather constructive macro...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Total assets under management (AUM) at the world’s 500 largest asset managers reached USD 128.0 trillion at the end of 2023, according to new research from leading global advisory, broking and solutions company WTW’s (NASDAQ: WTW) Thinking Ahead Institute. Despite not yet reaching 2021 levels, this amounts to 12.5% annual growth and marks a significant recovery from the major correction the year before (AUM dropped by $18 trillion in 2022). The research also reveals the continued evolution of active vs. passive assets under management among the largest investment managers. For the first time, passive investment strategies now account for more than one third of AUM among the 500 largest firms (33.7%), though this still leaves almost two thirds of assets managed by the world’s largest managers...

Shareholders Approve The New Strategy And Instalment of new Board Schiltigheim, October 21th 2024 18:00, Tonner Drones is pleased to announce that all resolutions has passed during the General Meeting of shareholders today. With 26,92% of the share capital present, the quorum was reached. All resolutions were passed with a large majority of the votes. From today, David Cloetingh and Olaf Graeff have been installed on the new board. Also, the extension of the articles of association was approved by shareholders. This allows TonnerDrones to roll out its new investment strategy. The documentation from the OEGM will be published on the website of Tonner Drones. About Tonner Drones: Tonner Drones (formerly Delta Drone) develops technologies for the logistics sector and has a promising product for stabilizing drones after recoil. Tonner Drones...

On 25 September 2024, the shareholders of Vastned Belgium approved the proposed reverse cross-border legal merger at an extraordinary general meeting of shareholders. Hereby, Vastned Retail, the current Dutch parent company of Vastned Belgium, will merge with and into Vastned Belgium. The proposed merger will take effect on 1 January 20251. On 25 September 2024, the shareholders of Vastned Belgium approved the distribution of an intermediary dividend (tussentijds dividend) for a gross amount of € 1.00 per share under the condition precedent of the proposed merger not proceeding. The coupon of this intermediary dividend was detached on 27 September 2024 and will be paid on 7 January 2025 to the pre-merger shareholders of Vastned Belgium. EPRA earnings of € 1.92 per share for the first nine (9) months of 2024, compared to € 2.10 per share...

Communiqué de presse         Lyon – Saint-Vulbas, le 21 octobre 2024 à 18h00 CHIFFRE D’AFFAIRES DU T3 2024 : 53,8 M€soit un recul de 1,3% vs T3 2023 Chiffre d’affaires cumulé à fin septembre : – 2,6% vs 2023En M€ T3 2023 T3 2024 9 mois 2023 9 mois 2024Europe 51,2 50,7 165,6 161,7Amérique du Nord 0,5 0,5 1,5 1,5Asie et reste du Monde 2,8 2,6 8,3 7,7Total à Périmètre courant 54,5 53,8 175,4 170,9Total à PC* 54,1 53,8 174,0 170,9          *à PC (à périmètre comparable) ORAPI enregistre sur le troisième trimestre 2024 un chiffre d’affaires de 53,8 M€ contre 54,5 M€ au T3 2023, soit un repli de – 1,3% à périmètre courant, qui intègre l’arrêt des activités de la filiale scandinave en novembre 2023. A périmètre comparable, le repli est de – 0,6%. A fin septembre 2024, ORAPI a ainsi réalisé un chiffre d’affaires...

Paris, 21 October 2024, 06:00pm Issuer Name: Rubis (LEI: 969500MGFIKUGLTC9742)Category of securities: Ordinary shares (ISIN: FR0013269123)Period: From 14 to 18 October 2024 In accordance with the authorisation granted by the Ordinary Shareholders’ Meeting held on 11 June 2024 to implement a share buyback programme, the Company operated, between 14 and 18 October 2024, the purchases of its own shares in view of their cancelation presented below. Aggregate presentation per day and per marketName of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)RUBIS 969500MGFIKUGLTC9742 14/10/2024 FR0013269123 2,931 25.1214 AQEURUBIS 969500MGFIKUGLTC9742 14/10/2024 FR0013269123 19,209 25.2339 CEUXRUBIS 969500MGFIKUGLTC9742 14/10/2024 FR0013269123 3,736 25.0963 TQEXRUBIS 969500MGFIKUGLTC9742 14/10/2024 FR0013269123 33,694 25.0730 XPARRUBIS 969500MGFIKUGLTC9742 15/10/2024 FR0013269123 3,426 24.9295 AQEURUBIS 969500MGFIKUGLTC9742 15/10/2024 FR0013269123 18,686 24.9241 CEUXRUBIS 969500MGFIKUGLTC9742 15/10/2024 FR0013269123 3,322 24.8144 TQEXRUBIS 969500MGFIKUGLTC9742 15/10/2024 FR0013269123 34,624 24.8668 XPARRUBIS 969500MGFIKUGLTC9742 16/10/2024 FR0013269123 1,623 24.9580 AQEURUBIS 969500MGFIKUGLTC9742 16/10/2024 FR0013269123 18,815 24.8383 CEUXRUBIS 969500MGFIKUGLTC9742 16/10/2024 FR0013269123 1,768 24.8737 TQEXRUBIS 969500MGFIKUGLTC9742 16/10/2024 FR0013269123 36,185 24.9009 XPARRUBIS 969500MGFIKUGLTC9742 17/10/2024 FR0013269123 12,705 25.0118 CEUXRUBIS 969500MGFIKUGLTC9742 17/10/2024 FR0013269123 36,792 25.0143 XPARRUBIS 969500MGFIKUGLTC9742 18/10/2024 FR0013269123 1,028 25.2043 AQEURUBIS 969500MGFIKUGLTC9742 18/10/2024 FR0013269123 13,424 25.1421 CEUXRUBIS 969500MGFIKUGLTC9742 18/10/2024 FR0013269123 205 25.2200 TQEXRUBIS 969500MGFIKUGLTC9742 18/10/2024 FR0013269123 34,473 25.1522 XPAR*...